Therefore, the assessment of KRAS/PIK3CA mutational status may be particularly important to predict prognosis of patients with pT1 CRC submitted to endoscopic conservative treatments in the aim to identify patients at high risk of metastatic diffusion and worse outcome, who could be submitted to surgery and adjuvant treatments. The gene discussed is KRAS; the disease is colorectal carcinoma.